The use of Selective Serotonin Re-uptake Inhibitors (SSRIs) in the treatment of depressive disorders in children and adolescents

Epidemiologia e Psichiatria Sociale

Volumn 14, Issue 2, 2005, Pages 63-67

  James, Anthony ^a,b  

^a Highfield Family and Adolescent Unit Oxford   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MIRTAZAPINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADOLESCENT DISEASE; ADVISORY COMMITTEE; BEHAVIOR THERAPY; CHILD; CHILD PSYCHIATRY; CHILDHOOD DISEASE; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG SUBSTITUTION; DRUG USE; EDITORIAL; HUMAN; PRACTICE GUIDELINE; PSYCHOPHARMACOTHERAPY; RESEARCH ETHICS; SIDE EFFECT; SUICIDE;

EID: 21344451214     PISSN: 1121189X     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1121189X00006266     Document Type: Editorial

References (44)

1. American College of Neuropsychopharmacology (2004). Executive Summary. Preliminary Report of Task Force on SSRIs and Suicidal Behaviour in Youth. Retrieved January 11, 2005 from http://www.acnp.org/exec_summary.pdf
2. BBC News (2003). Panorama: Seroxat: E-mails from the edge. Retrieved January 11, 2005 from http://news.bbc.co.uk/1/hi/programmes/panorama/2982797.stm
3. Brent D.A. & Birmaher B. (2004). British warnings on SSRIs questioned. Journal American Academy of Child and Adolescent Psychiatry 43, 379-380.
4. Carlsten A., Waern M., Ekedahl A. & Ranstam J. (2001). Antidepressant medication and suicide in Sweden. Pharmacoepidemiology and Drug Safety 10, 525-530.
5. Committee on Safety of Medicines (2003). Selective Serotonin Reuptake inhibitors (SSRIs) - overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents: summary of clinical trials. London: Committee on Safety of Medicines. Retrieved January 12, 2005 from http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed /safetymessages/SSRIfinal.pdf
6. Compton S.N., March J.S., Brent D., Albano A.M., Weersing V.R. & Curry J. (2004). Cognitive-behavioral psychotherapy for anxiety and depressive disorders in children and adolescents: an evidence-based medicine review. Journal of the American Academy of Child and Adolescent Psychiatry 43, 930-959.
7. Emslie G.J., Rush A.J., Weinberg W.A., Kowatch R.A., Hughes C.W., Carmody T. & Rintelmann J. (1997). A double-blind, randomised, placebo-controlled trial of Fluoxetine in children and adolescents with depression. Archives of General Psychiatry 54, 1031-1037.
8. Emslie G.J., Heiligenstein J.H., Wagner K.D., Hoog, S.L., Ernest D.E., Brown E., Nilsson M. & Jacobson J.G. (2002). Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. American Academy of Child and Adolescent Psychiatry 41, 1205-1215.
9. Fergusson D.M. & Woodward L.J. (2002). Mental health, educational, and social role outcomes of adolescents with depression. Archives of General Psychiatry 59, 225-231.
10. Garland E.J. (2004). Facing the evidence: antidepressant treatment in children and adolescents. Canadian Medical Association 170, 489-1345.
11. Gray D., Moskos M. & Keller T. (2003). Utah Youth Suicide Study New Findings. Presented at the Annual Meeting of the American Association of Suicidology, Sante Fe, New Mexico.
12. Gunnell D. & Ashby D. (2004). Antidepressants and suicide: what is the balance of benefit and harm. British Medical Journal 329(7456), 34-38.
13. Harrington R., Whittaker J., Shoebridge P. & Campbell F. (1998). Systematic review of efficacy of cognitive behaviour therapies in childhood and adolescent depressive disorder. British Medical Journal 316, 1559-1563.
14. Hawton K., Rodham K., Evans E. & Weatherall R. (2002). Deliberate self harm in adolescents: self report survey in schools in England. British Medical Journal 325, 1207-1211.
15. Hawton K., Hall S., Simkin S., Bale L., Bond A., Codd S. & Stewart A. (2003). Deliberate self-harm in adolescents: a study of characteristics and trends in Oxford, 1900-2000. Journal of Child Psychology and Psychiatry 44, 1191-1198.
16. Hazell P., O'Connell D., Heathcote D., Robertson J. & Henry D. (1995). Efficacy of tricyclics drugs in treating child and adolescent depression: a meta-analysis. British Medical Journal 310, 897-901.
17. Hazell P., O'Connell D., Heathcote D. & Henry D. (2002). Tricyclic drugs for depression in children and adolescents. Cochrane Database of Systematic Reviews, Issue 2.
18. Healy D. 2003). Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychotherapy and Psychosomatics 72, 71-79.
19. Isacsson G. (2000). Suicide prevention-a medical breakthrough? Acta Psychiatrica Scandanavica 102, 113-117.
20. Isacsson G., Holmgren P., Druid H. & Bergman U. (1997). The utilisation of antidepressants - a key issue in the prevention of suicide: an anlysis of 5281 suicides in Sweden during the period 1992-1994. Acta Psychiatrica Scandanavica 96, 94-100.
21. Jick H., Kaye J.A. & Jick S.S. (2004). Antidepressants and the risk of suicidal behaviours. Journal of the American Medical Association 292, 338-343.
22. Jureidini J.N., Doecke C.J., Mansfield P.R., Haby M.M., Menkes D.B. & Tonkin A.L. (2004). Efficacy and safety of antidepressants for children and adolescents. British Medical Journal 328, 879-883.
23. Keller M.B., Ryan N.D., Strober M., Klein R.G., Kutcher S.P., Birmaher B., Hagino O.R., Koplewicz H., Carlson G.A., Clarke G.N., Emslie G.J., Feinberg D., Geller B., Kusumakar V., Papatheodorou G., Sack W.H., Sweeney M., Wagner K.D., Weller E.B., Winters N.C., Oakes R. & McCafferty J.P. (2001). Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry 40, 762-772.
24. Khan A., Khan S., Kolts R. & Brown W.A. (2003). Suicide rates in clinical trial of SSRIs, other antidepressants, and placebo: analysis of FDA reports. American Journal of Psychiatry 160, 90-792.
25. Mandoki M.W., Tapia M.R., Tapia M.A., Sumner G.S. & Parker J.L. (1997). Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacology Bulletin 33, 149-154.
26. McClure M. (2001). Suicide in children and adolescents in England and Wales 1970-1998. British Medical Journal 178, 469-474.
27. Mufson L., Dorta P., Wickramaratne P., Nomura Y., Olfson M. & Weissman M.M. (2004). A randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents. Archives of General Psychiatry 61, 577-584.
28. Nutt D.J. (2003). Death and dependence: current controversies over the selective serotonin reuptake inhibitors. Journal of Psychopharmacology 17, 355-364.
29. Ohberg A., Vuori E., Klaukka T. & Lonnqvist J. (1998). Antidepressants and suicide mortality Journal of Affective Disorders 50, 225-233.
30. Olfson M., Shaffer D., Marcus S.C. & Greenberg T. (2003). Relationship between antidepressant medication treatment and suicide in adolescents. Archives of General Psychiatry 60, 978-982.
31. Pich J., Carne X., Arnaiz J.A., Gomez B., Trilla A. & Rodes J. (2003). Role of a research ethics committee in follow-up and publication of results. Lancet 361, 1015-1016.
32. Poznanski E.O. & Mokros H.B. (1996). Manual: Children's Depression Rating Scale-Revised. Western Psychological Services: Los Angeles.
33. Poznanski E.O., Cook S.C. & Carroll B.J. (1979). A depression rating scale for children. Pediatrics 64, 442-450.
34. a). Treatment of major depressive disorder in children and adolescents: most selective serotonin reuptake inhibitors are no longer recommended. British Medical Journal 328, 518-520.
35. Ramchandani P. (2004b). A question of balance: how safe are the medicines that are prescribed to children? Nature 430, 401-402.
36. Rao U., Weissman M.M., Martin J.A. & Hammond R.W. (1993). Childhood depression and risk of suicide: preliminary report of a longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry 32, 21-27.
37. Simeon J.G., Dinicola V.F., Fergusson H.B. & Copping W. (1990). Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Progress in Neuro-Psychopharmacology & Biological Psychiatry 14, 791-795.
38. Treatment for Adolescents With Depression Study Team (2004). Fluoxetine, cognitive-behavioral therapy, and their contribution for adolescent with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. Journal of American Medical Association 292, 807-820.
39. US Food and Drugs Administration (2004). FDA Statement on Recommendations of the Psychopharmacologic Drugs and Pediatric Advisory Committee. Retrieved January 11, 2005 from http://www.fda.gov/bbs/topics/news/2004/NEW01116.html
40. Wagner K. D., Ambrosini P., Rynn M., Wohlberg C., Yang R., Greenbaum M.S., Childress A., Donnelly C. & Deas D. (2003). Sertraline Pediatric Depression Study GroupEfficacy of sertraline in the treatment of children and adolescents with major depressive disorder. Journal of the American Medical Association 290, 1033-1041.
41. Wagner K.D., Robb A.S., Findling R.L., Jin J., Gutierrez M.M. & Heydorn W.E. (2004). A randomised, placebo-controlled Trial of citalopram for the treatment of major depression in children and adolescents. American Journal Psychiatry 161, 1079-1083.
42. Wessely S. & Kerwin R. (2004). Suicide risk and the SSRIs. Journal of the American Medical Association 292, 379-381.
43. World Health Organisation (2003). Suicide Prevention and special programmes. Country reports and charts available. Retrieved January 11, 2005 from http://www.who.int/mental_health/prevention/suicide/country_reports/en/
44. Whittington C.J., Kendall T., Fonagy P., Cottrell D., Cotgrove A. & Boddington E. (2004). Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363, 341-1345.